Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo (p<0.001). Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.